Alivus Life Sciences Ltd. Fundamental Analysis (NSE: ALIVUS.NS)
Alivus Life Sciences Ltd. Fundamental Analysis (NSE: ALIVUS.NS)
Alivus Life Sciences Ltd. (NSE: ALIVUS.NS) shows moderate financial fundamentals with a PE ratio of 27.50, profit margin of 23.28%, and ROE of 19.74%. The company generates $25.9B in annual revenue with moderate year-over-year growth of 7.59%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 87.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze ALIVUS.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentALIVUS.NS demonstrates superior asset utilization.
Valuation Score
ModerateALIVUS.NS shows balanced valuation metrics.
Growth Score
ExcellentALIVUS.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentALIVUS.NS maintains a strong and stable balance sheet.
Profitability Score
ExcellentALIVUS.NS achieves industry-leading margins.
Key Financial Metrics
Is ALIVUS.NS Expensive or Cheap?
P/E Ratio
ALIVUS.NS trades at 27.50 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ALIVUS.NS's PEG of 1.28 indicates fair valuation.
Price to Book
The market values Alivus Life Sciences Ltd. at 4.98 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 18.90 times EBITDA. This signals the market has high growth expectations.
How Well Does ALIVUS.NS Make Money?
Net Profit Margin
For every $100 in sales, Alivus Life Sciences Ltd. keeps $23.28 as profit after all expenses.
Operating Margin
Core operations generate 29.25 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $19.74 in profit for every $100 of shareholder equity.
ROA
Alivus Life Sciences Ltd. generates $15.14 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Alivus Life Sciences Ltd. produces operating cash flow of $4.33B, showing steady but balanced cash generation.
Free Cash Flow
Alivus Life Sciences Ltd. produces free cash flow of $2.39B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $19.48 in free cash annually.
FCF Yield
ALIVUS.NS converts 1.44% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
27.50
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.28
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.98
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.40
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.21
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.15
vs 25 benchmark
ROCE
Return on capital employed
0.22
vs 25 benchmark
How ALIVUS.NS Stacks Against Its Sector Peers
| Metric | ALIVUS.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 27.50 | 30.97 | Better (Cheaper) |
| ROE | 19.74% | 515.00% | Weak |
| Net Margin | 23.28% | 30197.00% | Weak |
| Debt/Equity | 0.02 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 5.21 | 5.71 | Strong Liquidity |
| ROA | 15.14% | -16.00% (disorted) | Strong |
ALIVUS.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Alivus Life Sciences Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
7.41%
Industry Style: Defensive, Growth, Innovation
GrowingEPS CAGR
16.05%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
37.39%
Industry Style: Defensive, Growth, Innovation
High Growth